Search

Your search keyword '"Schankin, Christoph J."' showing total 373 results
Start Over Author "Schankin, Christoph J."
373 results on '"Schankin, Christoph J."'

2. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results

Author

Gantenbein, Andreas R., Bonvin, Christophe, Kamm, Christian P., Schankin, Christoph J., Zecca, Chiara, Zieglgänsberger, Dominik, Merki-Feld, Gabriele Susanne, Pohl, Heiko, Rudolph, Nicole, Ryvlin, Philippe, Agosti, Reto, Schäfer, Elisabeth, Meyer, Ina, Kulartz-Schank, Monika, and Arzt, Michael E.

Published
2024
Full Text
View/download PDF

6. Changes of migraine aura with advancing age of patients

Author

Scutelnic, Adrian, Drangova, Hristina, Klein, Antonia, Slavova, Nedelina, Beyeler, Morin, Lippert, Julian, Silimon, Norbert, Meinel, Thomas R., Arnold, Marcel, Fischer, Urs, Riederer, Franz, Mattle, Heinrich P., Jung, Simon, and Schankin, Christoph J.

Published
2023
Full Text
View/download PDF

9. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P.

Published
2023
Full Text
View/download PDF

14. Erratum zu: Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P.

Published
2023
Full Text
View/download PDF

15. The potential to prevent unnecessary emergency department visits by timely diagnosis of migraine–A prospective observational study.

Author

Drangova, Hristina, Kofmel, Nicole, Branca, Mattia, Gloor, David, Lehmann, Beat, Exadaktylos, Aristomenis, Jung, Simon, Fischer, Urs, and Schankin, Christoph J.

Subjects
EMERGENCY room visits, MEDICAL personnel, MIGRAINE, DIAGNOSTIC errors, HOSPITAL emergency services, SUMATRIPTAN
Abstract

Aim: Successful acute migraine treatment potentially prevents emergency room (ER) consultations but requires that the diagnosis of migraine was given earlier. The aim of this study is to quantify the problem of missed migraine diagnosis prior to ER visits. Methods: Inclusion criterion for this single-center prospective study was the presentation at the ER for acute headache. Patients with acute migraine attacks were assessed for previous migraine attacks, and whether they were given a diagnosis of migraine in the past. Results: Of 137 patients with migraine diagnosis at discharge, 108 (79%) had previous headache attacks fulfilling the criteria for migraine according to The International Classification of Headache Disorders 3rd edition (ICHD-3). Of those, 54 (50%) received the diagnosis for the first time. Conclusion: Half of the migraine patients (50%) presenting in the ER for headache could have been diagnosed earlier. This highlights the need for better detection and treatment of migraine by pre-hospital healthcare providers, as earlier diagnosis and specific acute treatment could have prevented the ER visit. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Patient-reported symptomatology and its course in spontaneous intracranial hypotension – Beware of a chameleon

Author

Jesse, Christopher Marvin, primary, Schär, ScharRalph T., additional, Goldberg, Johannes, additional, Fung, Christian, additional, Ulrich, Christian Thomas, additional, Dobrocky, Tomas, additional, Piechowiak, Eike Immo, additional, Schankin, Christoph J., additional, Beck, Jürgen, additional, Raabe, Andreas, additional, and Häni, HaniLevin, additional

Published
2023
Full Text
View/download PDF

23. Circannual worsening in cluster headache correlates with daylight change.

Author

Riederer, Franz and Schankin, Christoph J.

Subjects
*SEASONAL affective disorder, *SEASONS, *MATHEMATICS, *BRAIN, *DESCRIPTIVE statistics, *PHOTOTHERAPY, *CLUSTER headache, *CIRCADIAN rhythms, *CONCEPTUAL structures, *SEROTONIN receptors, *DATA analysis software, *TIME
Abstract

Plain Language Summary: Cluster headache attacks typically occur with circadian rhythmicity and seasonal variability.In this article, we show that circannual rhythmicity of cluster headache attacks with its peak occurrence in spring and autumn could be explained by the rapidity in daylight alterations over the photoperiod, which is not constant but maximal at the time of equinoxes in spring. The peak of cluster attack occurrence at the equinoxes in spring and autumn coincides with greater leaps in day length, leading to interfere with synchronization of endogenous pacemaker systems. Interactions with the serotonergic system, also following circannual fluctuations are discussed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

Author

Ashina, Messoud, primary, Mitsikostas, Dimos D., additional, Amin, Faisal Mohammad, additional, Kokturk, Pinar, additional, Schankin, Christoph J., additional, Sahin, Gurdal, additional, Pozo-Rosich, Patricia, additional, Dorman, Paul J., additional, Nežádal, Tomáš, additional, Poole, Anne Christine, additional, Martins, Isabel Pavão, additional, Sumelahti, Marja-Liisa, additional, Ramirez Campos, Verena, additional, Ahn, Andrew H., additional, Lyras, Leonidas, additional, and Tassorelli, Cristina, additional

Published
2023
Full Text
View/download PDF

32. Symptomatic visual snow in acute ischemic stroke: A case series

Author

Scutelnic, Adrian, Slavova, Nedelina, Klein, Antonia, Horvath, Thomas, De Beukelaer, Sophie A L, Arnold, Marcel, Jung, Simon, and Schankin, Christoph J

Subjects
Neurology, Neurology (clinical), 610 Medizin und Gesundheit
Abstract

Visual snow is the main symptom of visual snow syndrome, a disorder of predominantly visual disturbances initially described in patients without abnormalities on ancillary investigations. We present a case series of patients with visual snow in the setting of acute ischemic stroke. The first and second patient reported previous episodic visual snow with migraine attacks. The third patient experienced visual snow for the first time during the ischemic stroke. In the first patient, the ischemic stroke affected the right and left precuneus and the right lingual gyrus. In the second patient, the ischemic stroke was located in the left lingual gyrus, parts of the left fusiform and parahippocampal gyrus, left dorso-lateral thalamus, and left cerebellar hemisphere. In the third patient, occipital pole, trunk of the corpus callosum on the right, right paramedian pons, right cerebellar hemisphere, and vermis were affected. Our case series indicates that the symptom visual snow can be caused by vascular lesions in areas of visual processing. Because patients did not meet criteria for visual snow syndrome, dysfunction in the affected areas might only explain part of the complex pathophysiology of visual snow syndrome.

Published
2023

36. Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: Second Interim Analysis of the Observational PEARL Study (P12-12.002)

Author

Ashina, Messoud, primary, Mitsikostas, Dimos D., additional, Amin, Faisal M., additional, Kokturk, Pinar, additional, Sahin, Gurdal, additional, Schankin, Christoph J., additional, Dorman, Paul J., additional, Pozo-Rosich, Patricia, additional, Lyras, Leonidas, additional, Myers, Coleen, additional, Ahn, Andrew H., additional, and Tassorelli, Cristina, additional

Published
2023
Full Text
View/download PDF

37. Real-world effectiveness of fremanezumab for the preventive treatment of migraine:Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

Author

Ashina, Messoud, Mitsikostas, Dimos D., Amin, Faisal Mohammad, Kokturk, Pinar, Schankin, Christoph J., Sahin, Gurdal, Pozo-Rosich, Patricia, Dorman, Paul J., Nežádal, Tomáš, Poole, Anne Christine, Martins, Isabel Pavão, Sumelahti, Marja Liisa, Ramirez Campos, Verena, Ahn, Andrew H., Lyras, Leonidas, Tassorelli, Cristina, Ashina, Messoud, Mitsikostas, Dimos D., Amin, Faisal Mohammad, Kokturk, Pinar, Schankin, Christoph J., Sahin, Gurdal, Pozo-Rosich, Patricia, Dorman, Paul J., Nežádal, Tomáš, Poole, Anne Christine, Martins, Isabel Pavão, Sumelahti, Marja Liisa, Ramirez Campos, Verena, Ahn, Andrew H., Lyras, Leonidas, and Tassorelli, Cristina

Abstract

Background The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. Methods Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1–12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1–12. Safety was assessed through adverse events reported. Results Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1–12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. Conclusion PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries., Background: The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. Methods: Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1–12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1–12. Safety was assessed through adverse events reported. Results: Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1–12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. Conclusion: PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries. Trial registration: encepp.eu: EUPAS35111.

Published
2023

40. Erratum zu: Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, primary, Förderreuther, Stefanie, additional, Ruscheweyh, Ruth, additional, Ruschil, Victoria, additional, Sprenger, Till, additional, Lewis, David, additional, Kamm, Katharina, additional, Freilinger, Tobias, additional, Neeb, Lars, additional, Malzacher, Volker, additional, Meier, Uwe, additional, Gehring, Klaus, additional, Kraya, Torsten, additional, Dresler, Thomas, additional, Schankin, Christoph J., additional, Gantenbein, Andreas R., additional, Brössner, Gregor, additional, Zebenholzer, Karin, additional, Diener, Hans-Christoph, additional, Gaul, Charly, additional, and Jürgens, Tim P., additional

Published
2023
Full Text
View/download PDF

43. Response to erenumab assessed by HIT-6 is modulated by genetic factors and arterial hypertension - an explorative cohort study

Author

Zecca, Chiara, Terrazzino, Salvatore, Para, Davide, Campagna, Giovanna, Viana, Michele, Schankin, Christoph J, and Gobbi, Claudio

Subjects
610 Medicine & health
Abstract

BACKGROUND Response predictors to erenumab (ERE) in migraine patients would benefit their clinical management. We investigate associations between patients' clinic characteristics and polymorphisms at CALCRL and RAMP1 genes and response to ERE treatment measured as clinically meaningful improvement of the headache impact test 6 (HIT-6) score. METHODS Post-hoc analysis of a prospective, multicenter, investigator-initiated study involving 110 migraine patients starting ERE 70 mg/month. Demographics, medical history, and migraine-related burden measured by HIT-6 score were collected during 3 months before and after ERE start. Selected polymorphic variants of calcitonin receptor-like receptor and receptor activity-modifying protein-1 genes were determined using Real-time PCR. Logistic regression models identified independent predictors for response to ERE, defined as HIT-6 score improvement ≥8 points (HIT-6 responders [HIT-6RESP], vs. HIT-6 non-responders [HIT-6NRESP]). RESULTS At month 3, 58 (52.7%) patients were HIT-6RESP. Comorbid hypertension predicted a lower probability of being HIT-6RESP [OR (95%CI] 0.160 (0.047-0.548), p=0.003). Compared to major alleles, minor alleles CALCRL rs6710852G and RAMP rs6431564G conferred an increased probability of being HIT-6RESP [for each G allele: OR (95%CI): 2.82(1.03-7.73), p=0.043; OR 95%CI): 2.10(1.05-4.22), p=0.037]. RAMP1 rs13386048A and RAMP1 rs12465864G decreased this probability [for each rs13386048A, OR (95%CI): 0.53(0.28-0.98), p=0.042; for each rs12465864G, OR(95%CI): 0.32(0.13-0.75), p=0.009). A genetic risk score based on the presence and number of identified risk alleles resulted independently associated with HIT-6RESP (OR, 0.49; 95%CI, 0.33-0.72; p= 0.0003) surviving Bonferroni's correction. CONCLUSIONS Response to ERE was associated with comorbid hypertension and specific allelic variants at CALCRL and RAMP1 genes. Results require confirmation in future studies.

Published
2023
Full Text
View/download PDF

44. [Untitled]

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J, Gantenbein, Andreas R, Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P

Subjects
610 Medizin und Gesundheit
Published
2023
Full Text
View/download PDF

45. [Untitled]

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J, Gantenbein, Andreas R, Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P

Subjects
610 Medicine & health
Published
2023
Full Text
View/download PDF

46. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, primary, Förderreuther, Stefanie, additional, Ruscheweyh, Ruth, additional, Ruschil, Victoria, additional, Sprenger, Till, additional, Lewis, David, additional, Kamm, Katharina, additional, Freilinger, Tobias, additional, Neeb, Lars, additional, Malzacher, Volker, additional, Meier, Uwe, additional, Gehring, Klaus, additional, Kraya, Torsten, additional, Dresler, Thomas, additional, Schankin, Christoph J., additional, Gantenbein, Andreas R., additional, Brössner, Gregor, additional, Zebenholzer, Karin, additional, Diener, Hans-Christoph, additional, Gaul, Charly, additional, and Jürgens, Tim P., additional

Published
2022
Full Text
View/download PDF

47. Migraine aura-like symptoms at onset of stroke and stroke-like symptoms in migraine with aura

Author

Scutelnic, Adrian, primary, Kreis, Lukas A., additional, Beyeler, Morin, additional, Heldner, Mirjam R., additional, Meinel, Thomas R., additional, Kaesmacher, Johannes, additional, Hakim, Arsany, additional, Arnold, Marcel, additional, Fischer, Urs, additional, Mattle, Heinrich P., additional, Schankin, Christoph J., additional, and Jung, Simon, additional

Published
2022
Full Text
View/download PDF

49. Epidural Blood Patching in Spontaneous Intracranial Hypotension—Do we Really Seal the Leak?

Author

Piechowiak, Eike I., primary, Aeschimann, Benjamin, additional, Häni, Levin, additional, Kaesmacher, Johannes, additional, Mordasini, Pasquale, additional, Jesse, Christopher Marvin, additional, Schankin, Christoph J., additional, Raabe, Andreas, additional, Schär, Ralph T., additional, Gralla, Jan, additional, Beck, Jürgen, additional, and Dobrocky, Tomas, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results